Roswell Biotechnologies, Inc., headquartered in the United States, is a pioneering company in the biotechnology sector, specialising in advanced genomic sequencing technologies. Founded in 2016, Roswell has rapidly established itself as a leader in the development of innovative solutions for DNA and RNA analysis, catering to both research and clinical applications. The company’s flagship product, the Roswell Biotechnologies’ platform, offers unique capabilities in high-throughput sequencing, enabling researchers to conduct comprehensive genomic studies with unprecedented accuracy and efficiency. With a commitment to advancing personalised medicine, Roswell Biotechnologies has achieved significant milestones, including collaborations with major research institutions and recognition for its contributions to the field. As a key player in the biotechnology landscape, Roswell Biotechnologies continues to drive innovation, positioning itself at the forefront of genomic research and diagnostics.
How does Roswell Biotechnologies, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Roswell Biotechnologies, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2020, Roswell Biotechnologies, Inc. reported total carbon emissions of approximately 29,443,000 kg CO2e. This figure includes Scope 1 emissions of about 10,281,000 kg CO2e, Scope 2 emissions of around 9,840,000 kg CO2e, and Scope 3 emissions totalling approximately 9,322,000 kg CO2e. The company has disclosed emissions data across all three scopes, demonstrating a comprehensive approach to tracking its carbon footprint. Despite the significant emissions reported, Roswell Biotechnologies has not established specific reduction targets or initiatives as part of its climate commitments. There are no climate pledges or SBTi (Science Based Targets initiative) targets currently in place, indicating a potential area for future development in their sustainability strategy. As of now, there is no cascaded emissions data from a parent or related organization, suggesting that the reported figures are solely from Roswell Biotechnologies, Inc. itself. The company operates within a sector that increasingly prioritises climate action, and the absence of defined reduction targets may present challenges in aligning with industry standards for sustainability.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | |
|---|---|
| Scope 1 | 10,281,000 |
| Scope 2 | 9,840,000 |
| Scope 3 | 9,322,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Roswell Biotechnologies, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.